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Introduction
Tremendous advances have been made over the past two
decades in determining the molecular genetic basis for
human inherited diseases. Mutations in an impressive
number of genes have been linked with specific clinical
conditions. Much of this work has focused on elucidat-
ing the genes associated with disorders that demonstrate
Mendelian inheritance. Disorders with Mendelian in-
heritance are, by definition, “single-gene” disorders; that
is, individuals with the mutated gene are at risk of having
the disease, whereas individuals in the same kindredwho
do not carry the mutation are not at risk.
One hope of molecular genetic diagnosis has been that
it may offer the ability to predict clinical status from the
genotype. However, for many of these Mendelian con-
ditions, genotype-phenotype correlations have proved
elusive (Beaudet et al. 2001; Scriver 2002). In other
words, the factors that govern translation of risk for a
disease, which is conferred by genotype, into phenotypic
clinical disease have often remained unclear. The im-
precise prediction of phenotype on the basis of the pres-
ence of a mutation is clinically apparent in the frequent
occurrence of broad variability in phenotypic expres-
sion within a single family. A mutation in a gene that
can either cause clinical signs or have no recognized phe-
notypic effect is not uncommon, and this fact is reflected
in the concept of reduced penetrance. Thus, not only is
the severity of disease often difficult to predict on the
basis of the specific mutation but, in some cases, whether
or not someone will even be affected can also be unclear.
It is well recognized that for several monogenic condi-
tions in which mutations in a single gene are believed to
account for all cases of the disease (e.g., cystic fibrosis
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and phenylketonuria), there may be important genetic
modifiers of expressivity (Haldane 1949; Scriver andWa-
ters 1999; Dipple and McCabe 2000b).
For most conditions, the molecular bases of variable
expressivity and reduced penetrance are not well delin-
eated. Variation in environmental exposures may con-
tribute to the phenotype (Scriver 2002). In addition, as
we highlight in this review, it is likely that at least part
of the clinical variability is due to abnormalities in other
genes that act in the same or interacting developmental
pathways (Vockley et al. 2000; Nadeau 2001; McCabe
2002). Factors that influence phenotypic variability in-
clude functional activity thresholds of proteins, modifier
genes, and systems dynamics (Dipple and McCabe
2000a, 2000b; Dipple et al. 2001). Two thresholds of
mutant protein function were proposed: a level below
which the phenotype was always severe and a level
above which the phenotype was always mild (Dipple
and McCabe 2000a, 2000b). The dynamics of biolog-
ical networked systems predicts that disease is most
likely to occur if the activity of a protein that is func-
tionally linked to a large number of other proteins is
altered (Dipple et al. 2001). This is supported by the
recent descriptions of digenic inheritance in several hu-
man diseases (table 1). In digenic inheritance, mutations
in each of two unlinked genes are present in a single
individual, and the combination of the two genetic hits
causes a disease phenotype that is not apparent when
an individual carries only one of these gene alterations.
In the present report, we focus on molecular findings
demonstrating that, for several human diseases, digenic
inheritance can either cause disease or affect the severity
of the phenotype. We hypothesize that for some con-
ditions, specifically those that originate during early em-
bryogenesis, alterations in modifier genes or interactions
with environmental factors are required for full ex-
pression of the disease (multiple-hit hypothesis). Wewill
focus, in particular, on holoprosencephaly (HPE), a se-
vere and common developmental defect of the fore-
brain. This condition is etiologically heterogeneous, be-
cause a mutation in any one of several genes has been
identified in affected patients. In addition, a number of
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Table 1
Digenic Inheritance in Human Disease
EFFECT AND
PHENOTYPE
GENE 1 GENE 2
REFERENCEMutation Phenotype Mutation Phenotype
Synergistic:
RP ROM1/G80insG Normal RDS/L185P Normal Kajiwara et al. 1994
RP ROM1/L114insG Normal RDS/L185P Normal Kajiwara et al. 1994
Bardet-Biedl BBS2Y24X/Q59X Normal BBS6/Q147X Normal Katsanis et al. 2001
Deafness GJB2/35delG Normal GJB6/ Normal Lerer et al. 2001
Deafness GJB2/167delT Normal GJB6/ Normal del Castillo et al. 2002
Hirschsprung RET/I6471I Normal EDNRB/S305N Normal Auricchio et al. 1999
Severe insulin resistance PPARG/A553delAAAiT Normal PPP1R3A/C1984delAG Normal Savage et al. 2002
Modifier:
Juvenile-onset glaucoma MYOC/G399V Adult-onset glaucoma CYP1B1/R368H Normal Vincent et al. 2002
Usher 1 USH3mut/mut Usher 3 MYO7A/delG (exon 25) Normal Adato et al. 1999
Congenital nonlethal JEB COL17A1R1226X/L855X Juvenile JEB LAMB3/R635X Normal Floeth et al. 1999
More severe ADPKD PKD1/mut Less severe ADPKD PKD2/2152delA Less severe ADPKD Pei et al. 2001
More severe hearing loss DFNA1 Mild hearing loss DFNA2 Mild hearing loss Balciuniene et al. 1998
WS2/OA MITF/944delA ?WS2 TYR/R402Q Normal Morell et al. 1997
More severe WS2/OA MITF/944delA ?WS2 TYRR402Q/R402Q Normal
NOTE.—The phenotypic description applies to the family reported in the reference only. mut p haplotype consistent with mutation in the
gene;  p wild type;  p partial deletion of gene.
environmental exposures can cause HPE. Thus, we sug-
gest that HPE is an example of a condition in which
multiple genetic and environmental influences can affect
the severity of the phenotype and that multiple hits are
required for severe manifestations of the condition.
Digenic Inheritance in Human Diseases
Retinitis Pigmentosa
Retinitis pigmentosa (RP) is characterized by pro-
gressive visual loss, night blindness, and pigmentary dep-
osition in the retina. RP is etiologically heterogeneous,
in that at least 26 different genes/loci have been de-
scribed (Wang et al. 2001). Several different genes have
been identified in autosomal dominant RP, including
RDS on 6p21 (MIM #179605). It is presently unclear
whether heterozygous mutations in ROM1 alone can
cause RP (Wang et al. 2001). Three pedigrees have been
described in which carriers of either a heterozygous
ROM1 orRDSmutation were unaffected. However, off-
spring who were heterozygous for both a ROM1 and
an RDS mutation had RP (Kajiwara et al. 1994). Both
gene products are involved in formation of a part of the
retina. ROM1 protein has been shown to interact with
RDS in the formation of an oligomeric transmembrane
protein complex in the rod outer-segment disks (Loewen
et al. 2001).
Bardet-Biedl Syndrome
Bardet-Biedl syndrome (MIM #209900) is an auto-
somal recessive disorder characterized by mental retar-
dation, retinal degeneration, polydactyly, and obesity. It
has been mapped to at least six loci: BBS1 (11q13),
BBS2 (16q21), BBS3 (3p13-p12), BBS4 (15q22.3),
BBS5 (2q31), and BBS6 (20p12) (Sheffield et al. 2001).
Four genes have been identified to date: BBS1, BBS2,
BBS4, and BBS6 (Katsanis et al. 2000; Slavotinek et al.
2000; Mykytyn et al. 2001, 2002; Nishimura et al.
2001). Mutations in BBS6, also termed “MKKS,” had
previously been found to causeMcKusick-Kaufman syn-
drome (Stone et al. 2000). Interestingly, when both the
BBS2 and BBS6 genes were screened, four pedigrees had
two mutated alleles for one of the genes and had one
normal and one mutated allele in the second gene (Kat-
sanis et al. 2001). In one of the pedigrees, an individual
who had two mutant alleles of BBS2 and two normal
BBS6 alleles was clinically unaffected, whereas the af-
fected individual had one mutated allele for BBS6, as
well as the two mutant alleles of BBS2. The potential
requirement for a third mutation in a second BBS gene
in addition to two mutations in the first BBS gene was
termed “triallelic” inheritance.
Deafness
Mutations in GJB2, which encodes connexin 26, are
the most frequent cause of nonsyndromic autosomal re-
cessive hearing loss in certain populations. Although
hearing loss associated with homozygous mutations in
GJB2 is prelingual, there is variability in its severity, and
it may be only mild (Cohn et al. 1999). Mutant alleles
of GJB6 (connexin 30) have also been associated with
hearing loss (Grifa et al. 1999). In an assessment of
Spanish families in which the inheritance pattern was
consistent with autosomal recessive inheritance and
whose members had only one detectedmutation inGJB2
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(the other allele was apparently normal), some had a
chromosomal deletion that truncated theGJB6 gene but
did not affect theGJB2 gene on that chromosome (Lerer
et al. 2001; del Castillo et al. 2002). Both connexins are
expressed in the inner ear and cochlea. In addition, they
can bind to each other to form gap-junction channels.
It was hypothesized that loss of any two of the four
alleles from GJB2 and GJB6 could result in hearing im-
pairment. Thus, either monogenic or digenic inheritance
can occur with these genes.
Evidence of digenic inheritance has also been reported
for nonsyndromic hearing loss involving the DFNA12
(chromosome 11q22-q24) and DFNA2 (chromosome
1p32) loci (Balciuniene et al. 1998), although the genes
had not yet been identified at the time of the report.
Increased severity of deafness was present in family
members who were carriers of both defective alleles.
Hirschsprung Disease
Hirschsprung disease is characterized by chronic
constipation due to absence of the ganglion cells in a
region of the intestine. It has been classified, by the extent
of involvement, into long-segment and short-segment
forms. It is an etiologically heterogeneous condition that
can be transmitted in an autosomal dominant fashion
(with incomplete penetrance) or as a multifactorial trait.
At least six different genes have been implicated in hu-
man Hirschsprung disease (Parisi and Kapur 2000). In
many pedigrees, it shows incomplete penetrance and var-
iable expressivity. Mutations in the RET gene have been
noted in both familial and sporadic cases (Parisi and
Kapur 2000). The penetrance of RET mutations is es-
timated to be 50%–70% (Bolk et al. 2000). RET is the
major gene involved in Hirschsprung disease, especially
the long-segment form. An individual with one abnor-
mal allele of RET (resulting in defective splicing) also
had a missense mutation in EDNRB (encoding the en-
dothelin-B receptor) (Auricchio et al. 1999).
In a few instances, mutations have been detected both
in the RET gene and in a gene encoding a RET ligand:
GDNF (which encodes glial cell line–derived neuro-
trophic factor) or NTN (which encodes Neurturin)
(Angrist et al. 1996; Salomon et al. 1996; Doray et al.
1998). For GDNF and NTN, a mutation in either gene
alone does not seem to be sufficient for development of
Hirschsprung disease in humans, and disease arises only
when a mutation in one of these genes occurs in the
presence of a RET mutation. The exact contribution of
NTN and GDNF to the development of Hirschsprung
disease is still unclear. An analysis of the short-segment
form demonstrated susceptibility loci at 3p21, 10q11,
and 19q12 (Bolk-Gabriel et al. 2002). The gene at 10q11
is most likely RET, and the 3p21 and 19q12 loci may
be RET-dependent modifiers (Bolk-Gabriel et al. 2002).
The data were believed to be most consistent with the
involvement of all three and with RET being the major
gene. In a study of Mennonite kindreds, RET, EDNRB,
and a locus at 16q23 were identified as susceptibility
loci (Carrasquillo et al. 2002).
An example of two genetic hits being found in the
same gene is provided by studies of RET (Fitze et al.
2002). The c135G/A polymorphism seemed to modify
the effect of RET germline mutations. The c135A allele
was found more frequently with short-segment disease
when it was on the same chromosome as the germline
mutation, whereas a RET germline mutation on the
c135G allele was associated with the long-segment phe-
notype. Fitze et al. speculated that the c135A allele had
what might be called a “protective” effect and was mod-
ifying the Hirschsprung phenotype. This finding sup-
ports the model of Hirschsprung disease in which phe-
notypes are influenced by differences both between and
within genes (McCabe 2002).
Insulin Resistance
Impaired response to insulin, or insulin resistance, is
present in individuals with type 2 diabetes. Familial cases
of severe insulin resistance, which may or may not be
associated with true diabetes, have been described. All
five affected members of a kindred with severe insulin
resistance had heterozygous frameshift/premature stop
codon mutations in two unlinked genes, PPARG and
PPP1R3A (Savage et al. 2002). No other family mem-
bers were compound heterozygotes for these two mu-
tations. Individuals carrying only one of the mutations
had normal fasting insulin levels. PPARG encodes per-
oxisome proliferator–activated receptor g (PPARg), a
protein that forms a heterodimer with the retinoid X
receptor that is activated by antidiabetic agonists. The
protein phosphatase 1, regulatory subunit 3 (PPP1R3A)
protein plays an important role in regulating glycogen
metabolism. The mutant PPP1R3A proteins had abnor-
mal cellular localization and were primarily located in
the cytosol, whereas normal protein is normally present
in intracellular membranes. It is of interest that PPARg
is primarily expressed in fat (although the protein is also
observed at low levels in muscle), and PPP1R3A is ex-
pressed only in muscle. Thus, although both proteins are
involved in the cellular response to insulin, it seems un-
likely that they directly interact.
Early-Onset Glaucoma
Glaucoma is a leading cause of blindness and is char-
acterized by irreversible loss of retinal ganglion cells,
visual field deficits, and an abnormal appearance of the
optic nerve head. Glaucoma can be characterized by
anatomy (open angle vs. closed angle) and time of onset
(infantile, juvenile, or adult onset). Onset of glaucoma
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at !40 years of age generally causes more severe visual
impairment than does glaucoma occurring at a later age
(MIM #137750). Juvenile open-angle glaucoma and pri-
mary adult-onset open-angle glaucoma can be caused by
mutations in the MYOC gene, which encodes the my-
ocilin protein, on chromosome 1q25, at the GLC1A
locus (Alward et al. 1998; Fingert et al. 1999). Muta-
tions in this gene account for ∼5% of sporadic primary
adult-onset open-angle glaucoma and for as much as
33% of familial cases of juvenile open-angle glaucoma
(Shimizu et al. 2000). There is significant inter- and in-
trafamilial variability in age at onset, rapidity of pro-
gression, and severity. Mutations in CYP1B1, at the
GLC3A locus, are present in a substantial proportion
of patients with congenital glaucoma (MIM #231300),
a recessive disease (Stoilov et al. 1997, 1998). The gene
encodes a member of the cytochrome p450 superfamily
and is located on chromosome 2p21. There is some de-
gree of variability in age at onset, and incomplete pen-
etrance has been noted (Bejjani et al. 2000). Both genes
are expressed in the iris, trabecular meshwork, and cil-
iary body of the eye. A Canadian family with autosomal
dominant glaucoma with both primary adult-onset and
juvenile forms of open-angle glaucoma showed segre-
gation of bothMYOC and CYP1B1mutations with dis-
ease. All affected family members carried the MYOC
mutation, and those with both mutations had juvenile
glaucoma, whereas those with only theMYOCmutation
had the adult-onset form. The mean age at onset of
disease among carriers of the MYOC mutation alone
was 51 years, whereas carriers of both the MYOC and
CYP1B1 mutations had an average age at onset of only
27 years (Vincent et al. 2002). Individuals carrying only
the CYP1B1mutation were not clinically affected. Thus,
in this family,CYP1B1 appears to be acting as a modifier
of MYOC.
Usher Syndrome
The Usher syndromes are autosomal recessive disor-
ders characterized by sensorineural hearing loss and RP.
Three different clinical types have been described:USH1,
USH2, and USH3, with USH1 being the most severe.
USH1B (MIM #276903) is due to mutations in the
MYO7A gene, on chromosome 11q13, which encodes
myosin VIIA (Weil et al. 1995; Weston et al. 1996).
USH3 maps to chromosome 3q (MIM #276902), and
the associated gene has recently been identified (Joensuu
et al. 2001). Other researchers have noted apparent di-
genic inheritance of deafness, involving the USH1B and
USH3 loci (Adato et al. 1999). Two affected brothers
were described in a Yemenite kindred, in which one
brother showed the USH1 phenotype, and the other
brother showed the USH3 phenotype. In both individ-
uals, linkage was consistent with the USH3 locus, not
theUSH1 orUSH2 loci, and both showed homozygosity
for four markers in the region of USH3. Mutations in
MYO7A were screened for, and an allele of MYO7A
with two nucleotide changes was present in the brother
with the USH1 phenotype but not in the brother with
the USH3 phenotype. Their mother and two unaffected
siblings were double heterozygotes for theMYO7A that
had the nucleotide changes and the “USH3 haplotype,”
but they did not have any hearing loss or other signs of
Usher syndrome. This suggested that the MYO7A mu-
tations may increase the severity of the disease as part
of the clinical symptoms associated with homozygous
mutations in USH3.
Epidermolysis Bullosa
Epidermolysis bullosa (EB) includes several disorders
featuring skin blisters, often provoked by friction or
trauma. In junctional EB (JEB), the blisters formbetween
the basal keratinocyte plasma membrane and the basal
lamina, and the hemidesmosomes are abnormal. The
form termed “generalized atrophic benign epidermolysis
bullosa” (GABEB) (MIM #226650) is an autosomal
recessive nonlethal subtype that is due, in most cases,
to mutations in the COL17A1 gene encoding collagen
XVII (McGrath et al. 1995). In the autosomal recessive
Herlitz type of JEB (MIM #226700), blisters develop at
birth, and the disease is lethal. Some cases are due to
mutations in LAMB3,which encodes the b3 polypeptide
subunit of laminin 5 (Kivirikko et al. 1996). Thus,
mutations affecting both alleles of either LAMB3 or
COL17A1 can be associated with JEB, although the dis-
ease is generally more severe in individuals with the
LAMB3 mutations. One patient was a compound
heterozygote for COL17A1 mutations and also had
a heterozygous mutation in LAMB3 (Floeth and
Bruckner-Tuderman 1999). Although there was con-
genital blistering, the subsequent course was more
mild than is typically seen in JEB-Herlitz. Individuals
who had one normal allele and one abnormal allele for
both COL17A1 and LAMB3 were clinically normal.
Thus, the LAMB3mutation appears to make the severity
of EB greater than that seen in most individuals with
COL17A1mutations. Both laminin 5 and collagen XVII
are components of the hemidesmosome-anchoring fila-
ment complex at the dermal-epidermal junction.
Autosomal Dominant Polycystic Kidney Disease
Individuals with autosomal dominant polycystic kid-
ney disease (ADPKD) (MIM #173900) are at risk of
renal failure. The disease generally presents in the third
to fifth decade of life, although presentations in child-
hood and infancy have been noted. ADPKD is most fre-
quently due to mutations in PKD1. Mutations in PKD2
have also been noted in a minority of patients, and mu-
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tations in a third gene have been detected in a small
number of patients. Most affected individuals have a
single mutation in either PKD1 or PKD2. Although
most cysts demonstrate loss of heterozygosity for the
remaining allele of PKD1 or PKD2, other cysts have
trans heterozygous mutations in both PKD1 and PKD2
(Koptides and Deltas 2000; Watnick et al. 2000). Thus,
at-risk individuals have a germline mutation in either
PKD1 or PKD2, and cyst formation occurs after there
is a second mutation. Interestingly, in a pedigree with
independently segregating PKD1 and PKD2 mutations,
individuals heterozygous for mutations in both genes
were more severely affected than those with only a single
gene mutation (Pei et al. 2001). The gene products of
PKD1 and PKD2, polycystin 1 and 2, interact to pro-
duce cation currents, which neither polycystin is able to
produce alone (Hanaoka et al. 2000).
Waardenburg Syndrome and Ocular Albinism
Waardenburg syndrome type II (WS2 [MIM#193510])
is an autosomal dominant condition characterized by
hypopigmentation and hearing loss. It is etiologically
heterogeneous, and some cases are due to mutations in
the MITF gene (Tassabehji et al. 1994), which encodes
a transcription factor. Ocular albinism (MIM #203100)
is also etiologically heterogeneous and can be due to
mutations in theTYR gene, which encodes the tyrosinase
enzyme (Spritz et al. 1990). WS2 in combination with
ocular albinism was noted in one kindred (Morell et al.
1997). A TYRR402Q mutation was present in either het-
erozygous or homozygous form in 13 members of the
family. All of the individuals with either hearing loss or
ocular albinism had a mutation in MITF, in addition to
the TYR mutation. This suggests that the WS2–ocular
albinism phenotype may result from the interaction be-
tween MITF and tyrosinase. MITF may act to regulate
TYR transcription (Bentley et al. 1994).
HPE: At the Crossroads between Mendelian and
Multifactorial Diseases
HPE is the most common developmental abnormality of
the forebrain (Muenke and Beachy 2001). It occurs as
frequently as 1 in 250 conceptuses and ∼1 in 16,000
live births (Roach et al. 1975; Matsunaga and Shiota
1977). The condition is characterized by incomplete sep-
aration of the forebrain into distinct right and left halves.
Affected regions include forebrain derivatives, such as
the cerebral cortex and thalamus. Some degree of mental
retardation occurs in most affected individuals. There is
a continuous gradation of severity of the brain malfor-
mation, from complete continuity of the two cerebral
hemispheres, to partial separation, to only slight con-
tinuity of the most ventral aspect of the hemispheres.
Associated craniofacial features are extremely variable
and occur in 80%–90% of patients with HPE (Cohen
1989). Facial anomalies can be striking and may include
cyclopia (single midline eye), nasal anomalies, and cleft
lip and palate. More mild manifestations include ocular
hypotelorism (closely spaced eyes), microcephaly, and a
single central maxillary incisor (Ming and Muenke
1998). When these milder craniofacial features occur in
the absence of HPE, they are termed “microforms” and
are generally associated with normal cognitive devel-
opment. AlthoughHPE usually occurs sporadically,mul-
tiple kindreds demonstrating autosomal dominant in-
heritance have been described. In familial HPE, there
can be extremely wide variation in type and severity of
brain and/or facial anomaly within a single kindred
(Muenke et al. 1994). Patients with HPE, individuals
with only microforms who have normal intelligence, and
clinically unaffected obligate carriers may be present in
a single pedigree. On the basis of analysis of autosomal
dominant pedigrees, it is estimated that, among carriers
of the abnormal gene, 37% will have HPE, and 27%
will have a mild sign (microform). Interestingly, 36% of
obligate carriers have no clinical abnormality and have
normal intelligence (Cohen 1989).
Genetics of Human HPE
HPE is etiologically heterogeneous, and both envi-
ronmental and genetic causes have been identified (Ming
et al. 1998). Substantial progress has beenmade towards
elucidating the genetic basis of HPE. Our initial studies
focused on chromosomal regions in which deletions
were associated with HPE (Roessler and Muenke 1998).
Analysis of recurrent rearrangements involving 7q36 led
to the identification of Sonic hedgehog (SHH) as the first
gene known to cause human HPE (Belloni et al. 1996;
Roessler et al. 1996). Mutations of this gene appear to
be the most common genetic cause of human HPE iden-
tified to date (Nanni et al. 1999). Mutations have been
detected in familial and sporadic cases (Roessler et al.
1996, 1997; Nanni et al. 1999; Odent et al. 1999). A
similar strategy was employed to identify mutations in
ZIC2 (Brown et al. 1998, 2001), SIX3 (Wallis et al.
1999), and TGIF (Gripp et al. 2000). Recently, muta-
tions associated with HPE have been found in other
genes selected as candidates because of their participa-
tion in a signaling pathway important for brain devel-
opment: PATCHED1 (PTCH) (Ming et al. 2002) and
GLI2 (M.M., unpublished data) in SHH signaling, and
TDGF1 (de la Cruz et al. 2002) and FAST1 (M.M.,
unpublished data) in the Nodal/transforming growth
factor b (TGF-b) pathway (fig. 1). The identification of
these eight genes associated with HPE demonstrates the
complexity of the genetic etiology of this condition.
However, mutations in these genes have been identified
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Figure 1 Association of HPE with abnormal signaling pathways and cholesterol biosynthesis and with ZIC2 and SIX3 transcription
factors. Some aspects of interactions are speculative, since not all links have been explicitly demonstrated experimentally and many of the links
are only suggestive. In addition, results have been synthesized from several species although they are depicted here for humans only. To date,
the following genes (blackened symbols) have been implicated in HPE in humans: SHH, PTCH, GLI2 in Sonic hedgehog signaling, TDGF1,
FAST1, TGIF in Nodal/TGF-b signaling, SIX3, and ZIC2 (updated and modified from Muenke and Beachy 2001).
in only 15%–20% of the HPE cases in our cohort of
patients with HPE in our cohort of affected individuals
with normal karyotypes. Thus, a number of other genes
are likely to be involved in HPE. Additional candidate
genes would include those that map to a chromosomal
region in which recurrent rearrangements are associated
with HPE, genes in which an animal model shows HPE,
genes involved in forebrain development, or genes that
encode a component of a signaling pathway associated
with HPE.
Is the Intrafamilial Variability in Human HPE Due to
Multiple Genetic Hits (Multigenic Inheritance)?
A perplexing question in familial HPE has been the
extreme variability, ranging from clinically normal in-
dividuals to patients with severe HPE. Of interest, some,
but not all, patients with a chromosomal deletion as-
sociated with HPE will actually have HPE. Although all
known patients with a 2p21 deletion (including SIX3)
have HPE, only ∼50% of patients with del(7)(q36) (in-
cluding SHH) and 10% of those with del(18p) (including
TGIF) have HPE (M.M., unpublished data). This implies
that haploinsufficiency for the respective gene is not gen-
erally sufficient to cause HPE and that other genetic or
environmental factors are likely to be involved. This con-
cept is supported by molecular genetic analysis of HPE
patients. An SHHmutation has been detected inmultiple
pedigrees, demonstrating autosomal dominant inheri-
tance of the HPE spectrum. Within one family, the same
SHH mutation may be present in individuals with HPE,
individuals with microforms, and asymptomatic family
members (Roessler et al. 1996). In fact, a clinically nor-
mal mother with an SHH mutation predicted to result
in premature termination of translation had a child with
HPE and the same mutation (Roessler et al. 1996). Thus,
the phenotype associated with a given SHH mutation
can be extremely variable, even in a parent and child.
This variability in phenotype has also been noted in
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association with mutations in the other HPE genes. We
hypothesize that despite its apparent transmission as a
“single-gene” autosomal dominant disease, HPE is ac-
tually a multifactorial condition, and the phenotype aris-
ing in any single individual is the cumulative result of
multiple genetic and environmental influences. We hy-
pothesize that, for the severe phenotype, multiple genetic
alterations and/or prenatal exposures to teratogens are
required. Inheritance of only one abnormal gene may
give rise to either a mild manifestation or no clinical
abnormality. We will first discuss evidence from animal
models that multiple genetic abnormalities may be re-
quired for HPE.
Mutations in Two HPE Genes in Individuals with HPE
The phenotypic spectrum of autosomal dominant
HPE is quite variable, and we postulate that any given
individual’s phenotype depends on the number and type
of HPE gene mutations present in that person. To date,
we have identified three patients who have a mutation
in both SHH and a second HPE gene (Nanni et al. 1999)
(fig. 2). The first patient with HPE has a deletion of
18p11, including the TGIF gene, and a mutation in SHH
(P424A). Interestingly, her phenotypically normal mother
has the same SHHmutation but carries a balanced trans-
location involving 18p, t(1;18)(q43;p11.3). Thus, the
mother has two copies of TGIF, but the daughter has
only a single allele (fig. 2A).
The second patient with HPE has a mutation in both
TGIF (T151A) and SHH (378-380del). Her clinically
normal mother has the mutation in SHH but has two
normal TGIF alleles (fig. 2B). The father was not avail-
able for study. The third patient with HPE has both a
ZIC2 (polyalanine expansion) and an SHH (G290N)
mutation (fig. 2C). Her parents were not available for
study. The fact that these patients have mutations in two
HPE genes raises the possibility that the two mutations
are combining to give rise to a more severe phenotype
than would the single mutation alone. This is supported
by the finding that the clinically normal parents that
were available for testing carried only one of the mu-
tations. Because a mutation in any of the HPE genes is
detected in only ∼15%–20% of patients with HPE, it is
unlikely that the two mutations occurred by chance in
each of three unrelated patients with HPE. Elsewhere,
we reported the finding of 23 different SHH mutations
in 344 patients with HPE (Nanni et al. 1999), 15 ZIC2
mutations in 509 patients with HPE (Brown et al. 2001),
and 4 TGIF mutations in 300 patients with HPE (Gripp
et al. 2000). Assuming Hardy-Weinberg equilibrium, the
expected probability of a double heterozygote for SHH/
TGIF is 0.0008, and the probability of SHH/ZIC2 is
0.0018. The difference between the expected and ob-
served (SHH/ ; SHH/ )TGIFp 0.0067 ZIC2p 0.0033
values of double heterozygotes is statistically significant
( , and , ,2 2x p 10.343 Pp .0012 x p 4.423 Pp .034
respectively). These data further suggest that it is the
cumulative effect of multiple genetic defects that may
determine the phenotype. Given the large number of
HPE-associated genes, the complexity suggested by the
variety of mutant alleles, and the fact that mutations
have been identified in only 20% of patients with HPE
to date, it is intriguing to speculate why, in one family
with SHHmutation, HPE microsigns (e.g., single central
incisor [SCI]) segregate with the mutation (fig. 2D);
whereas, in an unrelated family with a different SHH
mutation segregating with SCIs, a child is born with
severe HPE (fig. 2E).
The finding that two mutations are detected in some
patients with HPE may provide insight into why dose
sensitivity for SHH appears to vary between humans and
mice. That is, the Shh mutant homozygous mouse has
features of HPE and cyclopia and often dies during em-
bryonic development, whereas the heterozygous mouse
appears normal (Chiang et al. 1996). This is in contrast
to humans, in which haploinsufficiency for SHH is as-
sociated with HPE. This may reflect the fact that humans
with two mutated alleles of SHH are not likely to survive
past early gestation, and almost all patients studied are
live-born infants. We postulate that patients heterozy-
gous for an SHH mutation and no other genetic ab-
normalities in HPE genes will not have HPE and that
the patients with HPE also have a second mutation in
a distinct gene. The requirement of multiple genetic le-
sions may be more evident in humans, since it is unlikely
that any of these important developmental genes is truly
absent in live-born infants.
Animal Models of Digenic Inheritance of HPE
Several mouse mutants demonstrate that HPE can arise
from the co-occurrence of mutations in two different
genes (table 2). Mice that are mutant for both of the genes
may show HPE, whereas a mouse with only one of
the genes affected does not have HPE and often ap-
pears normal. For example, both nodal/; HNF3b/
(Varlet et al. 1997) and Otx2/; HNF3b/ (Jin et al.
2001) double heterozygotes show cyclopia and HPE. Cy-
clopia and reduction of anterior head structures were pre-
sent in a Smad2/; nodal/ double heterozygote (No-
mura and Li 1998) and in an ActRIIA (activin receptor
II) /; nodal/ double mutant (Song et al. 1999). In ad-
dition, bothNoggin/; Chordin/ andNoggin/;Chor-
din/ double mutants show defects consistent with HPE
(Bachiller et al. 2000; Klingensmith et al. 2001). Overall,
these data demonstrate that HPE can be due to digenic
inheritance in mouse models.
Figure 2 Pedigrees segregating different missense mutations in SHH. A–C, Patients with HPE and mutations in a second gene. D and E,
Individuals with HPE microsign (CS p choanal stenosis; P p ptosis of eyelids; OH p ocular hypotelorism) are depicted by half-blackened
symbols. One pedigree segregates an SHH (I111F) mutation (modified from Nanni et al. 2001) (D). One pedigree segregates an SHH (S236R)
mutation (modified from Nanni et al. 1999) (E). Patient photographs have been published elsewhere (Nanni et al. 1999 [patients in panels A,
C, and E], Nanni et al. 2001 [patient in panel D]; Gripp et al. 2000 [patient in panel B]) and are used with permission of the publishers.
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Table 2
Mouse Models of Digenic Inheritance of HPE
Mutant Mice Reference
nodal/; HNF3b/ Varlet et al. 1997
Otx2/; HNF3b/ Jin et al. 2001
Smad2/; nodal/ Nomura and Li 1998
Activin receptor II (ActRIIA)/; nodal/ Song et al. 1999
Noggin/; Chordin/ Bachiller et al. 2000
Noggin/; Chordin/ Klingensmith et al. 2001
Relationships between the HPE Genes
The human and animal data detailed above indicate
that abnormalities in two unlinked genes can have a
synergistic effect in causing HPE. Animal models indi-
cate that disruption of a number of distinct develop-
mental processes can bring about the common pheno-
type of HPE. First, early developmental effects during
gastrulation that result in loss of the prechordal plate,
an important source of the ventralizing signal Shh, can
lead to loss of ventral cell types, cyclopia, andHPE (Rub-
enstein and Beachy 1998). Chemical or physical ablation
of the prechordal plate at gastrulation can induce cy-
clopia and ventral forebrain defects (Rubenstein and
Beachy 1998). Several zebrafish mutants with an ab-
normal prechordal plate show cyclopia (e.g., cyclops,
squint, and one-eyed pinhead) (Schier et al. 1996; Schier
2001). Second, HPE can arise from a relatively late dis-
ruption after neural tube closure. For example, loss of
normal dorsal-ventral patterning after neural tube clo-
sure can result in HPE (Golden et al. 1999). Also, fore-
brain truncation defects with cyclopia (Schneider et al.
2001), similar to those seen in mouse models, have also
been induced at these later time points.
The relationships between some of the human HPE
genes are beginning to be understood (fig. 1). Shh is
critical for ventral forebrain induction; Patched is its
receptor; and Gli2 is a mediator of Shh target gene tran-
scription. Six3 is also expressed in the ventral forebrain,
and it may modulate the effect of Shh on the ventral
forebrain (Kobayashi et al. 2002). Any relationship be-
tween Zic2 and Shh is likely to be less direct, because
Zic2 is primarily expressed in the dorsal neural tube
(Nagai et al. 1997) and Shh expression is restricted to
the ventral neural tube. Zic proteins can bind to the same
target sequences as the Gli proteins, transcription factors
that regulate expression of Shh-responsive genes (Aruga
et al. 1994; Mizugishi et al. 2001). In addition, Zic2 can
alter Gli activity in neural patterning (Brewster et al.
1998).
The functional relationship between Tgif and Shh is
unknown. Tgif acts as a transcriptional co-repressor of
expression in TGF-b signaling (Wotton et al. 1999) (fig.
1). Disruption of Nodal, a member of the TGF-b su-
perfamily, leads to abnormal prechordal plate formation
and results in ventral forebrain deficits and cyclopia
(Schier et al. 1997; Zhang et al. 1998). It is of possible
relevance that another TGF-b family member, bone mor-
phogenetic protein 7, also acts in ventral forebrain de-
velopment in conjunction with Shh (Dale et al. 1997,
1999). Tgif has also been shown to act in retinoic
acid–receptor signaling (Bertolino et al. 1995), and re-
tinoic acid exposure can decrease Shh activity in the
craniofacial region (Helms et al. 1997). Overall, the un-
derstanding of the complex interplay among the differ-
ent HPE gene products is just beginning to emerge. Fur-
ther experimental information will determine whether
these different proteins act directly or indirectly in pro-
cesses that mediate forebrain development.
Teratogens Cause HPE and May Interact with HPE
Genes
Although it appears likely that multiple genes con-
tribute to the phenotype of human HPE, evidence from
both human studies and animal models implicate envi-
ronmental factors in the pathogenesis of HPE as well.
Maternal diabetes, including gestational diabetes, in-
creases the risk of HPE to ∼1%–2% of pregnancy out-
comes (Barr et al. 1983; Cohen 1989; Martinez-Frias et
al. 1998). Prenatal human exposure to ethanol (Ronen
and Andrews 1991; Croen et al. 2000; Cohen and Shiota
2002) has been associated with abnormalities of theHPE
spectrum. Animal models demonstrate that HPE can be
induced with ethanol exposure during gastrulation (Su-
lik and Johnston 1982) and may be due to interference
with prechordal plate function (Blader and Strahle
1998). HPE in humans has also been noted in association
with prenatal exposure to retinoic acid (Lammer et al.
1985; Cohen and Shiota 2002), although the degree of
increased risk is not known. Administration of retinoic
acid to pregnant mice induced craniofacial malforma-
tions consistent with HPE (Sulik et al. 1995). Retinoic
acid may affect Shh signaling (Helms et al. 1997; Schnei-
der et al. 2001).
There are several lines of evidence linking defective
cholesterol biosynthesis and HPE. First, ∼5%of children
with Smith-Lemli-Opitz syndrome (SLOS) show HPE or
malformations consistent with the HPE spectrum (Kelley
et al. 1996). SLOS is caused by a defect in the final step
of cholesterol synthesis, 7-dehydrocholesterol reductase
(7-DHCR) (Fitzky et al. 1998; Wassif et al. 1998). In-
terestingly, this enzyme is also inhibited by the chemical
AY9944, and animals exposed to this agent have HPE
(Roux et al. 1979; Muenke and Beachy 2001). In ad-
dition, the compounds cyclopamine and jervine are plant
alkaloids that induced outbreaks of cyclopia in flocks of
sheep that ate plants containing these compounds (Kee-
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ler and Binns 1968). These compounds inhibit choles-
terol biosynthesis (Mann and Beachy 2000). The mature
Shh molecule undergoes cholesterol modification (fig. 1;
Porter et al. 1996), although it is not clear how defective
cholesterol biosynthesis affects Shh signaling, and the
effect may actually be on other components of the path-
way (Taipale et al. 2000). The observation that only 5%
of children with SLOS have HPE (Kelley et al. 1996)
suggests that the mutation in 7-DHCR may require a
second genetic or environmental hit to produce the HPE
phenotype. When families of children with isolated HPE
were studied, significantly lower cholesterol values were
found in the mothers than in the fathers (M.M. and
Kelley, unpublished data). It is possible that low mater-
nal cholesterol levels during pregnancy may influence
the risk for HPE in the fetus. Overall, it appears that
decreased cholesterol levels during fetal development
may have adverse effects on brain development, whether
through environmental and/or genetic mechanisms. A
retrospective and a prospective study to address this pos-
sibility are in progress (M.M. and colleagues).
Taken together, data from both human studies and
animal models indicate that prenatal environmental ex-
posures can play a key role in the generation of HPE.
This raises the possibility that maternal levels of various
compounds could play a role in the pathogenesis of hu-
man HPE. Thus, endogenous maternal levels of choles-
terol or retinoic acid, exposure to ethanol, or subclinical
levels of maternal hyperglycemia may contribute to
HPE. We hypothesize that even relatively low doses of
these teratogens, which by themselves may not be suf-
ficient to cause HPE or any other clinical abnormality,
may act in concert with other environmental or genetic
variables to generate the HPE phenotype.
Conclusions
Overlap between Monogenic and Multigenic Diseases
The distinction between monogenic and multigenic
inheritance of disease is becoming increasingly blurred.
Traditionally, conditions were considered to follow ei-
ther Mendelian (single gene) or multifactorial (multiple
genes) inheritance patterns. However, the findings of in-
complete penetrance and variable expressivity for Men-
delian disorders clearly indicate that contributions apart
from the “single gene” play an important role in the
clinical outcomes of these patients (Beaudet et al. 2001).
For many Mendelian disorders, the cause of phenotypic
variability is likely to be the interplay between multiple
genetic and environmental factors. The demonstration
of digenic inheritance in human conditions indicates that
what are considered single-gene diseases may, in some
cases, be due to two or more genetic hits. Of note, many
of the conditions discussed (including HPE, Hirsch-
sprung disease, deafness, RP, and Bardet-Biedl syn-
drome) have significant genetic heterogeneity. In some
instances, homozygous mutations in a single gene can
also cause the disease in humans or animal models. Since
disruption of the function of any of several different
proteins can lead to the same phenotype, these proteins
are likely to functionally interact with each other. Thus,
we would anticipate that alterations of two proteins that
act in the same or interacting developmental pathways
could have compounding effects. Additional genetic in-
teractions will likely be identified for these diseases.
Classes of Digenic Inheritance
The relationships between the genes in digenic inher-
itance vary and may be classified into different catego-
ries. In the first group, the mutations in the two genes
seem to have a synergistic, or multiplicative, effect on
the phenotype (table 1). In these cases, mutations in each
of two genes are both required for manifestation of the
disease, and either of the hits alone is not sufficient to
cause symptoms (e.g., ROM1/RDS). In this situation, it
is not clear whether either gene has a greater influence
on the patient’s manifestations, and both genes could
contribute equally to the phenotypic expression. We
have termed these combinations “pathogenic” digenic
inheritance, since no phenotypic abnormality is clinically
apparent when only one gene mutation is present. The
phrase “synergistic heterozygosity” has been employed
to describe a similar situation in metabolic diseases
(Vockley et al. 2000). In synergistic heterozygosity, con-
current partial defects in more than one pathway, or at
multiple steps in a pathway, give rise to a clinically rel-
evant defect in energy metabolism, although the defect
in any one of the enzymes is not sufficient to cause a
significant deficit.
The question of whether a mutation in a major gene
is required for disease or whether different combinations
of genetic mutations also give rise to the same phenotype
awaits further study. If both mutations appear together
in individuals in successive generations, the trait may
appear to be transmitted in an autosomal dominant
manner. Identification of unaffected individuals who
have only one of the mutations will be needed for the
digenic inheritance to become apparent.
In the second group, mutations in the two genes may
appear to confer additive effects. We have termed these
combinations “modifier” digenic inheritance, because
a mutation in the first gene is sufficient to cause dis-
ease, but the second mutation in a different gene in-
creases its severity (PKD1/PKD2, COL7A1/LAMB3,
DFNA2/DFNA12, and MYOC/CYP1B1). In this case,
the second gene may act as a modifier of the first gene.
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Cumulative Effects of Genetic Abnormalities
Two genes that affect one another’s phenotypic effects
presumably must function in some common biologic
process (Vockley et al. 2000; McCabe 2002). The dif-
ferent types of interactions could also be classified into
different groups. First, the proteins may directly interact
with each other to form a structural component (e.g.,
polycystins 1 and 2, ROM1, and PRP1). Second, both
proteins could interact in the same signaling pathway
(e.g., RET and its ligand GDNF).
In another class of interactions, the two proteins do
not have a direct interaction. This could occur for two
proteins that are in the same signaling pathway but act
at distinct steps. For example, a ligand could induce,
through intracellular signaling, the activity of a tran-
scription factor. The proteins would be in the same path-
way but not have any direct physical interaction. The
modification, or buffering, of the phenotypic effect of a
mutation by an alteration of a second gene in the same
pathway or process has been termed “intrinsic” buffer-
ing (Hartman et al. 2001).
Alternatively, the proteins may not participate in the
same signaling pathway, but both are involved in the
same developmental process. There are several different
scenarios for this situation as well. First, one protein
may affect the cellular response to the second protein.
For example, Six3 and Shh are not known to directly
regulate one another’s expression or to act in the same
signaling pathway. However, Six3 seems to allow cells
to respond to Shh by expressing markers specific for the
anterior forebrain (Kobayashi et al. 2002). Second, the
two proteins may not modify each other’s cellular re-
sponses but, rather, may interact only in a broader sense,
in that both proteins may be independently involved in
the same developmental process. For example, two pro-
teins may both be involved in ventral patterning of the
forebrain but may not directly affect each other’s activ-
ity. Third, the two proteins may both impact develop-
ment of the same organ but at different developmental
times. For example, abnormalities in either prechordal
mesoderm formation or dorsal-ventral specification of
the forebrain can lead to HPE in animal models. In some
cases, the defect in dorsal-ventral patterning arises as a
result of abnormal prechordal mesoderm formation.
However, it is possible that mildly abnormal notochord
formation could still result in normal brain development.
Slightly decreased ventralizing activity in the neural tube
with normal prechordal mesoderm formation could, by
itself, be sufficient to result in normal forebrain devel-
opment. However, the two mild abnormalities could
synergize by both affecting the same process (ventral
patterning of the neural tube) and thus cause HPE.
Modification of the effect of one gene by the action of
another that is located in a biochemically distinct circuit
has been termed “extrinsic” buffering (Hartman et al.
2001). This would apply to scenarios in which processes
are redundant or complementary, such as a mutation in
an enzyme in DNA repair that exacerbates a defect in
DNA replication (Hartman et al. 2001).
For all of the scenarios indicated in which the two
proteins do not directly interact, molecular techniques
(such as two-hybrid screening) may not reveal the in-
teraction, and developmental biology models may be
required to demonstrate the functional interaction.
Environmental Influences and Other Factors
Environmental effects also play an important role in
determining phenotypic outcome. Aswith the interactions
between two proteins, environmental agents may influ-
ence protein function at several different levels. An agent
may reduce the cellular response to a protein by impairing
the activity of a signaling pathway (e.g., decreased cho-
lesterol leading to abnormal Shh signaling). Alternatively,
the environmental substance may regulate the expression
of a gene (e.g., retinoic acid and Shh), or the environ-
mental agentmay directly alter the protein’s function (e.g.,
retinoic acid receptor may compete for the same DNA
binding site as TGIF in HPE). Lastly, the environmental
agent could have a toxic effect on either the proliferation
or the survival of critical cell types. Prenatal environmen-
tal influences may not always be easy to determine, be-
cause different pregnancies presumably have differences
in intrauterine exposures. Even MZ twins may have dif-
ferent degrees of blood flow and thus, potentially, differ-
ent levels of exposure to teratogenic agents.
In addition to environmental and genetic effects, the
potential effects of stochastic contributions to develop-
ment could also play a role (Kirschner et al. 2000; Hart-
man et al. 2001). Stochastic events in developmental
biology are believed to govern immunoglobulin re-
arrangement on the DNA level, and it appears that the
determination of left-right situs is a random process in
certain mutant mice (Bisgrove and Yost 2001). Devel-
opmental events may not always be very precisely reg-
ulated; rather, there may be a range that results in normal
development. In the presence of a mutant gene, a low
normal level of development that has arisen because of
stochastic events may become apparent. For example, if
there is imprecision in the development of the prechordal
mesoderm such that a range of outcomes may be de-
velopmentally normal, it is possible that a low normal
amount of prechordal mesoderm activity in combination
with a genetic mutation that acts in the same pathway
could cause abnormal development.
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Summary
Multiple genetic and environmental factors likely play
a role in the phenotypic expression of many Mendelian
disorders. Understanding the biologic role of the genes
associated with human disease may guide future explo-
rations of additional modifier genes. For example, with
HPE, there are several possible categories of additional
candidate genes and potential sites of interaction. First,
there are genes encoding proteins that are in the signaling
pathways for identified disease genes (e.g., Shh and
nodal signaling). Second, genes involved in the relevant
developmental processes are potential candidate genes
for human diseases (dorsal-ventral patterning of the
forebrain, other processes in midline forebrain devel-
opment, prechordal mesoderm induction). Third, genes
involved in synthesis or metabolism of teratogenic agents
(cholesterol biosynthesis, retinoic acid metabolism)
could also be potential genetic contributors.
Multiple genetic hits or environmental exposures
may be required for clinical expression of many Men-
delian disorders. Conceptions of a disease being the
result of mutations in a single gene should take into
account the overlap between Mendelian and multifac-
torial disorders. Indeed, as more detail emerges dem-
onstrating the impact of genomic and environmental
variability on phenotype, we may reconceptualize clas-
sic Mendelian and complex multifactorial disorders as
two ends of a continuum of disease causation, with
the gradient reflecting the relative independence of a
given mutation in producing the disease phenotype. It
may be useful to remember that “genomes speak bi-
ochemistry, not phenotype” (Plasterk 1999). Future
studies will focus both on the identification of addi-
tional genes involved with these human diseases and
on the understanding of their biologic interactions.
Such information will lend greater insight into the
complex genetic and environmental influences that
lead to phenotypic expression of a trait.
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